Lilly to Present Latest Data for Taltz® (ixekizumab) in Psoriasis at the European Academy of Dermatology and Venereology (EADV) Annual Congress (NYSE:LLY)

INDIANAPOLIS, Sept. 27, 2016 /CNW/ -- Eli Lilly and Company (NYSE: LLY) will highlight clinical and patient-related health outcomes data evaluating Taltz^® (ixekizumab) for the treatment of adult patients with moderate-to-severe plaque psoriasis at the annual European Academy of Dermatology and Venereology Congress (EADV), which will take place Sept. 28-Oct. 2, 2016, in Vienna, Austria.



Lilly to Present Latest Data for Taltz® (ixekizumab) in Psoriasis at the European Academy of Dermatology and Venereology (EADV) Annual Congress (NYSE:LLY)